CWM
TEVA icon

Confluence Wealth Management’s Teva Pharmaceuticals TEVA Stock Holding History

Confluence Wealth Management’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		– Sell
-8,552
Closed -$448K – 118
2014
Q2 		$448K Buy
+8,552
New +$437K 0.26% 84

Other funds holding TEVA

Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
ACM
Americafirst Capital Management Roseville, California $74M AUM 13.49% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Lazard Asset Management
Lazard Asset Management New York $60.8B AUM 22.47% 1-Year Est. Return
MIP
Mondrian Investment Partners London, United Kingdom $6.69B AUM
WRF
Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return
Allianz Asset Management
Allianz Asset Management Munich, Germany $95.4B AUM 38.74% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Confluence Wealth Management's TEVA Position: Q3 2014 in Review

Confluence Wealth Management sold out of Teva Pharmaceuticals (TEVA) in Q3 2014, closing a stake of 8,552 shares — an estimated $448K sold.

Confluence Wealth Management first reported a position in TEVA in Q2 2014 and held it in 1 quarter. The position peaked at $448K in Q2 2014. 772 funds tracked by Wall St. Rank hold TEVA as of Q3 2014.

  • Confluence Wealth Management reported no remaining Teva Pharmaceuticals position as of Q3 2014 after selling out during the quarter.
  • Confluence Wealth Management sold 8,552 Teva Pharmaceuticals shares in Q3 2014, an estimated $448K.
  • Confluence Wealth Management first reported a position in Teva Pharmaceuticals in Q2 2014 and held it in 1 quarter.
  • Confluence Wealth Management's Teva Pharmaceuticals position peaked at $448K in Q2 2014.
  • 772 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q3 2014.

Based on Confluence Wealth Management's 13F filing for Q3 2014, filed 14 Nov 2014.